The impact of the Bundled Payment for Care Improvement Advanced on outcomes for patients with sepsis

高级护理改善捆绑付款对脓毒症患者预后的影响

基本信息

  • 批准号:
    10581829
  • 负责人:
  • 金额:
    $ 72.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-12-25 至 2022-12-26
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Sepsis is a devastating condition resulting from the immune system’s reaction to infection. 1.7 million Americans are hospitalized annually with sepsis, resulting in over 270,000 deaths. Sepsis is more common among older patients, leading to spending among Medicare beneficiaries totaling $41B in 2018. Treatment costs and episode spending also vary widely across hospitals, driven largely by differences in post-acute care. In an attempt to improve care, sepsis was included as one of the 31 inpatient episodes targeted under Medicare’s Bundled Payment for Care Improvement Advanced (BPCI-A) program. BPCI-A is a voluntary program that creates incentives for hospitals to improve patient outcomes and reduce spending across a 90- day post-discharge episode. BPCI-A has the potential to encourage hospitals to more effectively manage patients during the admission to avoid subsequent complications and to discharge patients to lower acuity post-acute settings. At the same time, BPCI-A is not designed primarily to improve quality, and changes in patient outcomes – positive or negative – will be closely tied to hospital efforts to reduce spending. Patients with Alzheimer’s disease and related dementias (ADRD) are both more likely to develop sepsis and to have worse outcomes. Patients with ADRD have very high episode spending and are particularly vulnerable to adverse outcomes following discharge, making their treatment for sepsis under BPCI-A critically important to understand. Outside of ADRD, how patient risk and sepsis care pathways influence patient outcomes for sepsis in the context of BPCI-A are not well understood. In this context, we propose the following aims: Aim 1. Evaluate the effects of BPCI-A on outcomes for patients with sepsis. We will link hospital participation in BPCI- A with national Medicare data to test the effects of the program on mortality, readmission, post-acute care, days alive and at home, burdensome transitions, and discharge to hospice. Aim 2. Evaluate the effects of BPCI-A on outcomes for sepsis patients with ADRD. Using validated Medicare claims algorithms to identify patients with ADRD, we will test the impact of BPCI-A on outcomes for patients with ADRD. Aim 3. Understand the relationship between clinical risk, treatment, and post-acute care treatment patterns and outcomes under BPCI-A. Using unique data from the Michigan Sepsis Initiative linked to Medicare claims data, we will identify the clinical treatment patterns, patient risk factors, and hospital characteristics that predict patient outcomes. We will examine whether hospitals participating in BPCI-A deploy a different set of strategies to manage patients with sepsis. Our proposal is significant because it combines national data with detailed clinical insights to understand the interplay between national policy and nuanced clinical care for patients with sepsis. Our proposal is innovative in its combination of administration and registry data sources coupled with sophisticated quantitative methods to answer a novel question.
项目总结 脓毒症是一种由免疫系统对感染的反应引起的毁灭性疾病。170万 美国人每年因脓毒症住院治疗,导致超过27万人死亡。脓毒症更常见 在老年患者中,导致2018年联邦医疗保险受益人的支出总计410亿美元。治疗 不同医院的费用和剧集支出也有很大差异,这在很大程度上是由急性后护理的差异推动的。 为了改善护理,脓毒症被列为下列31个目标住院病例之一 联邦医疗保险的高级护理改善捆绑付款(BPCI-A)计划。BPCI-A是一项志愿服务 该计划为医院创造激励措施,以改善患者的结果并减少90- 出院后一天的插曲。BPCI-A有可能鼓励医院更有效地管理 患者在入院期间避免后续并发症和出院时视力下降 急性后设置。同时,BPCI-A并不主要是为了提高质量而设计的,而且在 患者的结果--无论是积极的还是消极的--将与医院减少支出的努力密切相关。病人 患有阿尔茨海默病和相关痴呆(ADRD)的人更有可能发展为脓毒症和 更糟糕的结果。ADRD患者的病程费用非常高,尤其容易患上 出院后的不良后果,使他们在BPCI-A下对脓毒症的治疗至关重要 理解。在ADRD之外,患者风险和脓毒症护理路径如何影响患者预后 BPCI-A中的脓毒症还没有被很好地理解。在这方面,我们提出以下目标:目标1。 评价BPCI-A对脓毒症患者预后的影响。我们将把医院参与BPCI联系起来- A使用国家医疗保险数据来测试该计划对死亡率、再入院、急性后护理、 活着和在家的日子,繁重的过渡,以及出院到临终关怀。目标2.评估以下项目的效果 BPCI-A对脓毒症患者ADRD预后的影响。使用经过验证的Medicare索赔算法来识别 对于ADRD患者,我们将测试BPCI-A对ADRD患者预后的影响。目标3.理解 以下情况下临床风险、治疗和急性护理后治疗模式和结果的关系 BPCI-A。使用密歇根州败血症计划中链接到联邦医疗保险索赔数据的唯一数据,我们将确定 预测患者结局的临床治疗模式、患者风险因素和医院特征。 我们将检查参与BPCI-A的医院是否采用了一套不同的战略来管理 脓毒症患者。我们的建议意义重大,因为它将国家数据与详细的临床见解结合在一起 了解国家政策与脓毒症患者细微差别临床护理之间的相互作用。我们的 Proposal的创新之处在于它将管理和注册数据源与复杂的 用定量的方法来回答一个新问题。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andrew M Ryan其他文献

Andrew M Ryan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andrew M Ryan', 18)}}的其他基金

Evaluating the Effects of HACRP
评估 HACRP 的效果
  • 批准号:
    10412009
  • 财政年份:
    2018
  • 资助金额:
    $ 72.12万
  • 项目类别:
Evaluating the Effects of HACRP
评估 HACRP 的效果
  • 批准号:
    10745113
  • 财政年份:
    2018
  • 资助金额:
    $ 72.12万
  • 项目类别:
Evaluating the Effects of HACRP
评估 HACRP 的效果
  • 批准号:
    10166914
  • 财政年份:
    2018
  • 资助金额:
    $ 72.12万
  • 项目类别:
Comparative effectiveness of the sequential implementation of Hospital Value-Based Purchasing
医院价值采购序贯实施的效果比较
  • 批准号:
    9134666
  • 财政年份:
    2015
  • 资助金额:
    $ 72.12万
  • 项目类别:
The effects of bundled payment on acute cardiovascular outcomes among older adults
捆绑支付对老年人急性心血管结局的影响
  • 批准号:
    10440026
  • 财政年份:
    2015
  • 资助金额:
    $ 72.12万
  • 项目类别:
Comparative effectiveness of the sequential implementation of Hospital Value-Based Purchasing
医院价值采购序贯实施的效果比较
  • 批准号:
    8837212
  • 财政年份:
    2015
  • 资助金额:
    $ 72.12万
  • 项目类别:
Comparative effectiveness of the sequential implementation of Hospital Value-Based Purchasing
医院价值采购序贯实施的效果比较
  • 批准号:
    9308802
  • 财政年份:
    2015
  • 资助金额:
    $ 72.12万
  • 项目类别:
The Effects of Bundled Payment on Acute Cardiovascular Outcomes Among Older Adults
捆绑支付对老年人急性心血管结局的影响
  • 批准号:
    10732365
  • 财政年份:
    2015
  • 资助金额:
    $ 72.12万
  • 项目类别:
Estimating Hospital Outcome Quality: Applications to Pay-for-Performance
评估医院结果质量:按绩效付费的应用
  • 批准号:
    8261301
  • 财政年份:
    2010
  • 资助金额:
    $ 72.12万
  • 项目类别:
Estimating Hospital Outcome Quality: Applications to Pay-for-Performance
评估医院结果质量:按绩效付费的应用
  • 批准号:
    8102057
  • 财政年份:
    2010
  • 资助金额:
    $ 72.12万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 72.12万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 72.12万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 72.12万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了